Activin and Inhibin

LysRs-IN-2 is a lysyl-tRNA synthetase (KRS) inhibitor with IC 50 s of 0.015 μM and 0.13 μM for Plasmodium falciparum lysyl-tRNA synthetase ( Pf KRS) and Cryptosporidium parvum lysyl-tRNA synthetase ( Cp KRS), respectivelyIn VitroLysRs-IN-2 is active

LysRs-IN-2 is a lysyl-tRNA synthetase (KRS) inhibitor with IC 50 s of 0.015 μM and 0.13 μM for Plasmodium falciparum lysyl-tRNA synthetase ( Pf KRS) and Cryptosporidium parvum lysyl-tRNA synthetase ( Cp KRS), respectivelyIn VitroLysRs-IN-2 is active

LysRs-IN-2 is a lysyl-tRNA synthetase (KRS) inhibitor with IC 50 s of 0.015 μM and 0.13 μM for Plasmodium falciparum lysyl-tRNA synthetase ( Pf KRS) and Cryptosporidium parvum lysyl-tRNA synthetase ( Cp KRS), respectivelyIn VitroLysRs-IN-2 is active

M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC 50 =47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC 50 s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC

M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC 50 =47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC 50 s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC

M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC 50 =47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC 50 s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC

M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC 50 =47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC 50 s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC

M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC 50 =47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC 50 s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC

M‑1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regressionIn VitroM-1121 (0~100 nM: 24 hours: MV4:11 cells) drives dose-dependent down-regulation of HOXA9 and MEIS1

M-89 is a highly potent and specific menin inhibitor, with a K d of 1.4 nM for binding to menin. M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to treat MLL leukemiaForm:SolidIC50&amp:

M-89 is a highly potent and specific menin inhibitor, with a K d of 1.4 nM for binding to menin. M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to treat MLL leukemiaForm:SolidIC50&amp:

M-89 is a highly potent and specific menin inhibitor, with a K d of 1.4 nM for binding to menin. M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to treat MLL leukemiaForm:SolidIC50&amp: